Abstract 179P
Background
Exercise training reduces tumour growth by increasing tumour-infiltrating T cell density in preclinical models. However, it remains unknown whether exercise training can modify intratumoural T cells in humans. Objective: To compare the effects of exercise training intervention versus control on human prostate intratumoural T cell density.
Methods
This study is a secondary analysis of a randomised controlled trial. We randomly allocated men (age >18 years) with treatment-naïve localized prostate cancer scheduled to radical prostatectomy 2:1 to exercise training intervention or control. The exercise intervention consisted of supervised, high-intensity interval bicycling four times per week from the time of randomization until prostatectomy. Intratumoural CD3+ and CD8+ T cell densities in diagnostic biopsies and post-surgical prostatectomy specimens were quantified using immunohistochemistry. Between-group differences in changes from baseline to follow-up were estimated using constrained baseline linear mixed-effect models.
Results
A total of 30 participants were included (exercise intervention, n=20; control, n=10). We found no between-group differences in changes in CD3+ (mean difference [95% Cis]: –17 [–185; 150] cells/mm2) or CD8+ (mean difference [95% CI]: –16 [–206;172] cells/mm2) T cells. Additionally, we found no statistically significant correlations between changes in T cell density and the number of attended exercise training sessions or changes in maximal oxygen consumption.
Conclusions
In this secondary analysis of a randomised controlled trial, we found no impact of exercise training on tumour-infiltrating CD3+ and CD8+ T cell density in human prostate cancer.
Clinical trial identification
Local Ethics Committee of the Capital Region of Denmark (H-18020711). All participants provided informed consent before performing any study-related procedures, and the study was preregistered at www.clinicaltrials.gov (NCT03675529).
Legal entity responsible for the study
The authors.
Funding
TrygFonden and the Lundbeck Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract